The stock of PhaseRx Inc (NASDAQ:PZRX) is a huge mover today! About 30.56 million shares traded hands or 52363.52% up from the average. PhaseRx Inc (NASDAQ:PZRX) has risen 6.00% since October 29, 2016 and is uptrending. It has underperformed by 0.01% the S&P500.
The move comes after 8 months positive chart setup for the $32.11 million company. It was reported on Nov, 28 by Barchart.com. We have $2.88 PT which if reached, will make NASDAQ:PZRX worth $963,300 more.
Analysts await PhaseRx Inc (NASDAQ:PZRX) to report earnings on February, 6. After $-0.29 actual EPS reported by PhaseRx Inc for the previous quarter, Wall Street now forecasts -24.14% EPS growth.
According to Zacks Investment Research, “PhaseRx, Inc. is a preclinical biopharmaceutical company. It is engaged in developing products for the treatment of inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy. The Company’s i-ERT approach is enabled by its proprietary Hybrid mRNA Technology(TM) platform. PhaseRx, Inc. is headquartered in Seattle, Wash.”
More notable recent PhaseRx Inc (NASDAQ:PZRX) news were published by: Streetinsider.com which released: “Form 8-K PHASERX, INC. For: Nov 28” on November 28, 2016, also Marketwatch.com with their article: “PhaseRx Inc.” published on April 24, 2016, Prnewswire.com published: “PhaseRx Announces Positive Safety Results from Large Animal Study with Hybrid …” on November 08, 2016. More interesting news about PhaseRx Inc (NASDAQ:PZRX) were released by: Nasdaq.com and their article: “Mid-Day Market Update: Crude Oil Up Over 2%; PhaseRx Shares Spike Higher” published on November 28, 2016 as well as Prnewswire.com‘s news article titled: “PhaseRx Announces Pricing of Initial Public Offering” with publication date: May 18, 2016.
PZRX Company Profile
PhaseRx, Inc. is a biopharmaceutical firm developing a portfolio of mRNA products to correct life-threatening inherited liver diseases in children. The Company’s initial product development focus is on urea cycle disorders, a group of rare genetic diseases that generally present before the age of 12 and are characterized by the body’s inability to remove ammonia from the blood. The Company’s i-ERT approach is enabled by its Hybrid mRNA Technology platform and is applicable to a number of inherited liver diseases. The Firm is headquartered in Seattle.